Treatment Modalities for Leptomeningeal Metastases

Seminars in Oncology

Volumn 36, Issue SUPPL. 2, 2009, Pages

  Shapiro, William R ^a   Johanson, Conrad E ^b   Boogerd, Willem ^c  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b BROWN UNIVERSITY   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYTARABINE; METHOTREXATE; THIOTEPA;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID; CHOROID PLEXUS TUMOR; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DIFFUSION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MENINGEAL METASTASIS; PRIORITY JOURNAL; QUALITY OF LIFE; SINGLE DRUG DOSE; SOLID TUMOR; SURGICAL INFECTION; TREATMENT DURATION; WOUND INFECTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHOROID PLEXUS; HUMANS; INJECTIONS, SPINAL; MENINGEAL CARCINOMATOSIS;

EID: 67849129119     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.05.006     Document Type: Article

References (73)

1. Chamberlain M.C. Neoplastic meningitis. Neurologist 12 (2006) 179-187
2. Jaeckle K.A. Neoplastic meningitis from systemic malignancies; diagnosis, prognosis and treatment. Semin Oncol 33 (2006) 312-323
3. Kesari S., and Batchelor T.T. Leptomeningeal metastases. Neurol Clin 21 (2003) 25-66
4. Gleissner B., and Chamberlain M.C. Neoplastic meningitis. Lancet Neurol 5 (2006) 443-452
5. Johanson C.E., Duncan J.A., Stopa E.G., and Baird A. Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm Res 22 (2005) 1011-1037
6. Habgood M.D., Begley D.J., and Abbott N.J. Determinants of passive drug entry into the central nervous system. Cell Mol Neurobiol 20 (2000) 231-253
7. Ghersi-Egea J.F., Leininger-Muller B., Cecchelli R., and Fenstermacher J.D. Blood-brain interfaces: relevance to cerebral drug metabolism. Toxicol Lett (1995) 82-83 645-53
8. Grant R., Naylor B., Greenberg H.S., and Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 51 (1994) 457-461
9. Glantz M.J., Cole B.F., Recht L., Akerley W., Mills P., Saris S., et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. J Clin Oncol 16 (1998) 1561-1567
10. Shapiro W.R., Young D.F., and Mehta B.M. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293 (1975) 161-166
11. Balis R.M., Blaney S.M., McCully C.L., Bacher J.D., Jurphy R.F., and Poplack D.G. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol 45 (2000) 259-264
12. Hryniuk W.M., and Bertino J.R. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biomedical correlates. J Clin Invest 48 (1969) 2140-2155
13. Chabner B.A., and Young R. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52 (1973) 1804-1811
14. Green M.R., Chowdhary S., Lombardi K.M., Chalmers L.M., and Chamberlain M. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma. Expert Rev Neurother 6 (2006) 635-652
15. Strother D.R., Glynn-Barnhart A., and Kovnar E. Variability in the disposition of intraventricular methotrexate: A proposal for rational dosing. J Clin Oncol 7 (1989) 1741-1747
16. Bleyer W.A., Drake J.C., and Chabner B.A. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289 (1973) 770-773
17. Lopez J.A., Nassif E., Vannicola P., Krikorian J.G., and Agarwal R.P. Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol 3 (1985) 119-124
18. Slevin M.L., Piall E.M., Aherne G.W., Harvey V.J., Johnston A., and Lister T.A. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1 (1983) 546-551
19. DeAngelis L.M., Kreis W., Chan K., Dantis E., and Akerman S. Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. Cancer Chemother Pharmacol 29 (1992) 173-177
20. Sutoh H., Yamauchi T., Gotoh N., Sugiyama M., and Ueda T. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia. Anticancer Res 23 (2003) 5037-5042
21. Muldoon L.L., Soussain C., Jahnke K., Johanson C., Siegal T., Smith Q.R., et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25 (2007) 2295-2305
22. Kim L., and Glantz M.J. Neoplastic meningitis. Curr Treat Options Oncol 2 (2001) 517-527
23. Grossman S.A., Reinhard C.S., and Loats H.L. The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study. J Neurooncol 7 (1989) 319-328
24. Burch P.A., Grossman S.A., and Reinhard C.S. Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study. J Natl Cancer Inst 80 (1988) 1211-1216
25. Blasberg R.G., Patlak C., and Fenstermacher J.D. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195 (1975) 73-83
26. Blasberg R.G., Patlak C.S., and Shapiro W.R. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep 61 (1977) 633-641
27. Blasberg R.G. Methotrexate, cytosine arabinoside, and BCNU concentration in brain after ventriculocisternal perfusion. Cancer Treat Rep 61 (1977) 625-631
28. Bleyer W.A., and Poplack D.G. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: Prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 6 (1979) 207-213
29. Glantz M.J., Jaeckle K.A., Chamberlain M.C., Phuphanich S., Recht L., Swinnen L.J., et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5 (1999) 3394-3402
30. Kim S., Khatibi S., Howell S.B., McCully C., Balis F.M., and Poplack D.G. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res 53 (1993) 1596-1598
31. Rueda Dominguez A., Olmos Hidalgo D., Viciana Garrido R., and Torres Sanchez E. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clin Transl Oncol 7 (2005) 232-238
32. Chamberlain M.C., Kormanik P., Howell S.B., and Kim S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 52 (1995) 912-917
33. Cytarabine prescribing information (2000), Bedford Laboratories, Bedford, OH
34. Methotrexate prescribing information (2003), Xanodyne Pharmacal Inc, Floral, KY
35. Glantz M.J., Hall W.A., Cole B.F., Chozick B.S., Shannon C.M., Wahlberg L., et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75 (1995) 2919-2931
36. Chamberlain M.C., Kormanik P.A., and Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87 (1997) 694-699
37. Siegal T., Lossos A., and Pfeffer M.R. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 44 (1994) 1463-1469
38. Boogerd W., van der Sande J.J., and Moffie D. Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 51 (1988) 1277-1283
39. Grossman S.A., and Krabak M.J. Leptomeningeal carcinomatosis. Cancer Treat Rev 25 (1999) 103-119
40. Grossman S.A., Trump D.L., Chen D.C., Thompson G., and Camargo E.E. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111 indium-DTPA ventriculography. Am J Med 73 (1982) 641-647
41. Chamberlain M.C., and Corey-Bloom J. Leptomeningeal metastases: 111 indium-DTPA CSF flow studies. Neurology 41 (1991) 1765-1769
42. Chamberlain M.C., and Kormanik P.A. Prognostic significance of 111 indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 46 (1996) 1674-1677
43. Mason W.P., Yeh S.D., and DeAngelis L.M. 111 Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 50 (1998) 438-444
44. Chamberlain M.C., Nolan C., and Abrey L.E. Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol 75 (2005) 71-83
45. Chamberlain M.C. Chemotherapy for brain metastases due to lung cancer and melanoma. Cancer Treat Res 136 (2007) 199-213
46. Price S.A., and Polk Jr. H.C. Prophylactic and therapeutic use of antibiotics in pelvic surgery. J Surg Oncol 71 (1999) 261-268
47. Page C.P., Bohnen J.M., Fletcher J.R., McManus A.T., Solomkin J.S., and Wittmann D.H. Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. Arch Surg 128 (1993) 79-88
48. Shapiro W.R., Posner J.B., Ushio Y., Chemik N.L., and Young D.F. Treatment of meningeal neoplasms. Cancer Treat Rep 61 (1977) 733-743
49. Wasserstrom W.R., Glass J.P., and Posner J.B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49 (1982) 759-772
50. Yap H.Y., Yap B.S., Rasmussen S., Levens M.E., Hortobagyi G.N., and Blumenschein G.R. Treatment for meningeal carcinomatosis in breast cancer. Cancer 50 (1982) 219-222
51. Ongerboer de Visser B.W., Somers R., Nooyen W.H., van Heerde P., Hart A.A., and McVie J.G. Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33 (1983) 1565-1572
52. Clamon G., and Doebbeling B. Meningeal carcinomatosis from breast cancer: spinal cord vs. brain involvement. Breast Cancer Res Treat 9 (1987) 213-217
53. Jayson G.C., Howell A., Harris M., Morgenstern G., Chang J., and Ryder W.D. Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer 74 (1994) 3135-3141
54. Boogerd W., Hart A.A., van der Sande J.J., and Engelsman E. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67 (1991) 1685-1695
55. Bokstein F., Lossos A., and Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82 (1998) 1756-1763
56. Hitchins R.N., Bell D.R., Woods R.L., and Levi J.A. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5 (1987) 1655-1662
57. Grossman S.A., Finkelstein D.M., Ruckdeschel J.C., Trump D.L., Moynihan T., and Ettinger D.S. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11 (1993) 561-569
58. Boogerd W., van den Bent M.J., Koehler P.J., Heimans J.J., van der Sande J.J., Aaronson N.K., et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer 40 (2004) 2726-2733
59. Clatot F, Ouvrier M, Guillemet C, Veyret C, Blot E. Correlation of normalization of cerebrospinal fluid cytology (CSFC) with survival in breast cancer-related malignant meningitis (BMM) [abstract 1108]. Poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-June 3, 2008.
60. Kim S., Chatelut E., Kim J.C., Howell S.B., Cates C., Kormanik P.A., et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 11 (1993) 2186-2193
61. Phuphanich S., Maria B., Braeckman R., and Chamberlain M. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 81 (2007) 201-208
62. Johanson C.E. Choroid plexus-cerebrospinal fluid circulatory dynamics: impact on brain growth, metabolism, and repair. In: Conn P.M. (Ed). Neuroscience in medicine (2008), Humana Press, Totowa, NJ 173-200
63. Johanson C.E., Duncan III J.A., Klinge P.M., Brinker T., Stopa E.G., and Silverberg G.D. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res 5 (2008) 10
64. Johanson C.E. Arachnoid membrane, subarachnoid CSF and pia-glia. In: Pardridge W. (Ed). An introduction to the blood-brain barrier: methodology and biology (1998), Cambridge University Press, Cambridge 259-269
65. Mangurian L.P., Walsh R.J., and Posner B.I. Prolactin enhancement of its own uptake at the choroid plexus. Endocrinology 131 (1992) 698-702
66. Angelow S., Haselbach M., and Galla H.J. Functional characterization of the active ascorbic acid transport into cerebrospinal fluid using primary cultured choroid plexus cells. Brain Res 988 (2003) 105-113
67. Petito C.K. Human immunodeficiency virus type 1 compartmentalization in the central nervous system. J Neurovirol 10 Suppl 1 (2004) 21-24
68. Chen H., Wood C., and Petito C.K. Comparisons of HIV-1 viral sequences in brain, choroid plexus and spleen: potential role of choroid plexus in the pathogenesis of HIV encephalitis. J Neurovirol 6 (2000) 498-506
69. Levine S. Choroid plexus: target for systemic disease and pathway to the brain. Lab Invest 56 (1987) 231-233
70. + T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A 100 (2003) 8389-8394
71. Chodobski A., Chung I., Koüniewska E., Ivanenko T., Chang W., Harrington J.F., et al. Early neutrophilic expression of vascular endothelial growth factor after traumatic brain injury. Neuroscience 122 (2003) 853-867
72. Oldstone M.B., and Southern P.J. Trafficking of activated cytotoxic T lymphocytes into the central nervous system: use of a transgenic model. Neuroimmunology 46 (1993) 25-31
73. Lampson L.A. New animal models to probe brain tumor biology, therapy, and immunotherapy: advantages and remaining concerns. J Neurooncol 53 (2001) 275-287